---
title: consolidation therapy of acute myelogenous leukemia (AML)
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[acute myelogenous leukemia (AML)]]

# consolidation therapy of acute myelogenous leukemia (AML)

## If complete remissionÂ (CR) =
* ANC >103,
* plt >100,
* no RBC Rx,
* <5% BM blasts;Â 
* **CR â‰  cure**

---

* Favorable risk: high-dose cytarabine (HiDAC)
* Intermediate/Poor risk: Allo-HSCT

* Consider maintenance **azacitadine** if cannot complete curative intent RxÂ (NEJMÂ 2020;383:2526)

## Refractory/relapsed disease

* Repeating mutation analysisÂ b/c **clonal evolution common**

* FLT3-ITD/TKD mutation: **gilteritinib** (potent FLT3 inhibitor)

* IDH1Â mutation: ivosidenib;Â 
* IDH2Â mutation: enasidenib (small-molecule inhib of IDH1 or 2)

## Chemo
* MEC (mitoxantrone, etoposide, Ara-C)
* FLAG-Ida (fludarabine, Ara-C, G-CSF, & idarubicin)
* CLAM (clofarabine, Ara-C, mitoxantrone)
* gemtuzumab

